1. Home
  2. LC vs DVAX Comparison

LC vs DVAX Comparison

Compare LC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LC
  • DVAX
  • Stock Information
  • Founded
  • LC 2006
  • DVAX 1996
  • Country
  • LC United States
  • DVAX United States
  • Employees
  • LC N/A
  • DVAX N/A
  • Industry
  • LC Finance: Consumer Services
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LC Finance
  • DVAX Health Care
  • Exchange
  • LC Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • LC 1.5B
  • DVAX 1.5B
  • IPO Year
  • LC 2014
  • DVAX 2004
  • Fundamental
  • Price
  • LC $14.92
  • DVAX $12.21
  • Analyst Decision
  • LC Strong Buy
  • DVAX Buy
  • Analyst Count
  • LC 8
  • DVAX 2
  • Target Price
  • LC $15.38
  • DVAX $22.00
  • AVG Volume (30 Days)
  • LC 2.4M
  • DVAX 3.3M
  • Earning Date
  • LC 10-23-2024
  • DVAX 11-07-2024
  • Dividend Yield
  • LC N/A
  • DVAX N/A
  • EPS Growth
  • LC N/A
  • DVAX N/A
  • EPS
  • LC 0.46
  • DVAX 0.15
  • Revenue
  • LC $1,107,963,000.00
  • DVAX $260,810,000.00
  • Revenue This Year
  • LC N/A
  • DVAX $23.13
  • Revenue Next Year
  • LC $20.19
  • DVAX $19.60
  • P/E Ratio
  • LC $32.40
  • DVAX $80.80
  • Revenue Growth
  • LC N/A
  • DVAX N/A
  • 52 Week Low
  • LC $5.39
  • DVAX $9.74
  • 52 Week High
  • LC $16.16
  • DVAX $15.01
  • Technical
  • Relative Strength Index (RSI)
  • LC 59.74
  • DVAX 52.22
  • Support Level
  • LC $15.00
  • DVAX $11.61
  • Resistance Level
  • LC $16.16
  • DVAX $13.74
  • Average True Range (ATR)
  • LC 0.65
  • DVAX 0.52
  • MACD
  • LC -0.00
  • DVAX 0.09
  • Stochastic Oscillator
  • LC 51.56
  • DVAX 32.80

About LC LendingClub Corporation

LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: